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Human type 2 diabetes is associated with b-cell apoptosis, and human islets from diabetic donors
are 80% deﬁcient in PAK1 protein. Toward addressing linkage of PAK1 to b-cell survival, PAK1-siR-
NA targeted MIN6 b-cells were found to exhibit increased caspase-3 cleavage, cytosolic cytochrome-
C and the pro-apoptotic protein Bad. PAK1+/ heterozygous mouse islets recapitulated the upregula-
tion of Bad protein expression, as did hyperglycemic treatment of human or mouse islets; Bad levels
were exacerbated most in PAK1+/ islets subjected to hyperglycemic stress. These data implicate
PAK1 in b-cell survival via quenching of Bad protein expression, and suggest PAK1 as potential
molecular target to preserve b-cell mass.
 2012 Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.1. Introduction
Progressive deterioration in b-cell function and mass occurs in
the disease progression of type 2 diabetes (T2D). Reports suggest
that 50% of islets are in state of dysfunction or outright failure
at the time of diagnosis [1–3]. The serine/threonine p21-activated
kinase 1 (PAK1) is a ubiquitously expressed protein that is impli-
cated as a positive regulator of b-cell function; a paucity of PAK1
protein in islets is correlated with human T2D [4–6]. With regards
to this, PAK1 is implicated in the promotion of cell survival in neu-
ronal cells [7] and protective against ischemia/reperfusion injury in
cardiac cells [8,9]. However the role of PAK1 in b-cell survival has
never been assessed.
During the process of apoptosis, two dominant endogenous cell
fate regulators that target and block different steps from proceed-
ing are inhibitor of apoptosis proteins and the Bcl-2 family [10].
The pro-apoptotic protein Bad is a member of the Bcl-2 protein
family, and plays an important role in glucolipotoxicity induced
b-cell death in cultured human islets [11,12]. PAK1 has been
shown to be an important regulator of Bad proteins in vitro, phos-
phorylating Bad to inhibit its pro-apoptotic effects [13,14]. Phar-alf of the Federation of European B
., MS2031, Herman B Wells
p, Department of Pediatrics,macological inhibition of PAK1 activation results in reduced
phosphorylation of Bad, concurrent with increased apoptosis in
the H358 lung cancer and MPNST cell lines [13]. Whether PAK1
regulates Bad function in islet b-cells remains untested.
Herein, we examined a potential role of PAK1 in b-cell survival,
using multiple model systems: human islets, PAK1+/ heterozy-
gous mouse islets, and PAK1-depleted MIN6 b-cells. Our ﬁndings
reveal a role for PAK1 in maintaining Bad protein expression at
low levels in islet b-cells. Bad expression in islets was increased
by chronic exposure to hyperglycemic conditions, and could be in-
duced by depletion of PAK1 in the absence of glucose; PAK1+/ het-
erozygous islets subjected to hyperglycemia showed the largest
increase in Bad expression. Given that restoration of Pak1 to nor-
mal levels corresponded to reduced Bad expression, this suggests
that PAK1 is required to protect against b-cell apoptosis, particu-
larly under glucotoxic/hyperglycemic stress conditions, and that
attenuated PAK1 abundance could render islet b-cells more sus-
ceptible to apoptosis.
2. Materials and methods
2.1. Materials
The rabbit antibodies of PAK1, Bad, phospho-Bad(Ser112), Cas-
pase-3, Cytochrome-C were purchased from Cell Signaling (Dan-
vers, MA). Rabbit anti-actin was obtained from Santa Cruziochemical Societies.Open access under CC BY-NC-ND license.
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Fig. 1. Depletion of PAK1 increases expression of apoptotic factors in b-cells. MIN6
cells were transfected with PAK1 siRNA (siPAK1) or control (siCon) siRNA
oligonucleotides. After 48 h incubation, cells were washed twice and incubated
with glucose-free MKRBB for 2 h before harvesting. (A) Whole cell detergent lysates
were prepared and subjected to 12% SDS–PAGE for immunoblotting with antibodies
indicated. Data represent the average ± S.E. for three independent experiments;
⁄P < 0.05, versus siCon. (B) Cytosolic fractions were prepared as described in
Section 2.2. Cytosolic fraction protein was subjected to 15% SDS–PAGE for
immunoblotting (IB). Ponceau S staining was used as a protein loading control.
Data represent the average ± S.E. for three independent experiments; ⁄P < 0.05,
versus siCon.
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oxidase and anti-mouse horseradish peroxidase secondary anti-
bodies were acquired from Bio-Rad. Mouse PAK1 siRNA
oligonucleotide duplexes and siRNA non-targeting control oligonu-
cleotides were purchased from Ambion (Austin, TX) as described
previously [4]. Lipofectamine 2000, the SuperScript First Strand
cDNA Synthesis Kit and Platinum SYBR Green qPCR SuperMix-
UDG kit were purchased from Invitrogen. Enhanced chemilumines-
cence (ECL) reagent was obtained from Amersham Biosciences. D-
glucose was obtained from Sigma. The pCMV-myc-Pak1 and pCMV
vector plasmids were a gift from Dr. Lawrence Quilliam (Indiana
University School of Medicine, Indianpolis, IN).
2.2. Methods
2.2.1. Cell culture, transient transfection, and immunoblotting
MIN6 mouse pancreatic b-cells were cultured in DMEM
(25 mM glucose) supplemented with 15% fetal bovine serum,
100 units/ml penicillin, 100 lg/ml streptomycin, 292 lg/ml L-glu-
tamine, and 50 lM b-mercaptoethanol as described previously
[4]. For PAK1 depletion, MIN6 cells were transiently transfected
with PAK1 siRNA oligonucleotides duplexes along with pCMV6
vector plasmid or with pCMV6-myc-Pak1 plasmid as previously
reported [4] and incubated for 48 h. Cells were harvested in 1%
Nonidet P-40 lysis buffer and lysates cleared by centrifugation
at 14000g for 10 min at 4 C. Proteins present in lysates were
resolved by 12% or 15% SDS–PAGE, transferred to PVDF mem-
brane and subjected to immunoblotting. Membranes were incu-
bated with primary antibody at 4 C overnight, with secondary
antibodies conjugated to horseradish peroxidase used for 1 h at
room temperature. Bands were visualized by enhanced
chemiluminescence.
2.2.2. Mouse and human islets
The PAK1+/ heterozygous mouse is a classic whole-body gene-
ablation model on the C57Bl6J strain background, generated as
previously described [15]. All islets were obtained using paired lit-
termate mice as controls. Mouse pancreatic islets were isolated as
previously described [4]. Brieﬂy, pancreata from 10 to 16 week old
male mice were batch-digested with collagenase, puriﬁed using a
Ficoll density gradient, and incubated in CRML at 37 C, 5% CO2
for further experiments. All studies involving mice followed the
guidelines for the use and care of laboratory animals at the Indiana
University School of Medicine. Human islets were obtained
through the Integrated Islet Distribution Program (IIDP), accepted
under the following criteria: 75% or better viability and purity, nor-
mal BMI non-diabetic donor, obtained within 2 days of isolation.
Upon arrival islets were immediately hand-picked to exclude
non-islet material and placed in low or high-glucose CMRL for
5 days as described in the ﬁgure legend.
2.2.3. Subcellular fractionation
Cytosolic fractions were prepared from MIN6 b-cells as previ-
ously described [4]. Brieﬂy, MIN6 cells were washed with cold
phosphate-buffered saline and harvested into 1 ml of homogeni-
zation buffer (20 mM Tris–HCl, pH 7.4, 0.5 mM EDTA, 0.5 mM
EGTA, 250 mM sucrose, and 1 mM dithiothreitol containing the
following protease inhibitors: 10 lg/ml leupeptin, 4 lg/ml apro-
tinin, 2 lg/ml pepstatin, and 100 lM phenylmethylsulfonyl ﬂuo-
ride). Cells were disrupted by 10 strokes through a 27-gauge
needle, and homogenates were centrifuged at 900g for 10 min.
Postnuclear supernatants were centrifuged at 5500g for 15 min,
and the subsequent supernatant was centrifuged at 25000g for
20 min to obtain the secretory granule fraction in the pellet.
The supernatant was further centrifuged at 100000g for 1 h to
obtain the cytosolic fraction.2.2.4. Islet RNA isolation and quantitative PCR (Q-PCR)
Total RNA from mouse islets was obtained using the RNeasy
mini kit (Qiagen). RNA (0.5 mg) was reverse transcribed with the
SuperScript First Strand cDNA Synthesis Kit (Invitrogen), and 10%
of the product was used for Q-PCR. The primers used were as fol-
lows: Bad primers, forward 50-agagtatgttccagatcccag-30 and re-
verse 50-gtc ctcgaaaagggctaagc-30; GAPDH primers, forward 50-
atggtgaa ggtcggtgtgaacg and reverse 50-gttgtcatggatgaccttggcc.
The Q-PCR conditions were as follows: 50 C for 2-min hold
(UDG incubation), 95 C for 2-min hold, 40 cycles of 95 C for
15 s, and 60 C for 30 s.
2.2.5. Statistical analysis
Student’s t test was used to evaluate statistical signiﬁcance.
3. Results
3.1. PAK1 regulates expression of apoptotic factors in b-cells
To initiate study into the requirement for PAK1 in b-cell survival,
we ﬁrst employed MIN6 cells depleted of PAK1 using siRNA. Deple-
tion of PAK1 levels by50% signiﬁcantly increased caspase-3 cleav-
age levels by two-fold comparedwithcontrol siRNA-expressingcells
(siCon) (Fig. 1A). Moreover, we assessed cytosolic levels of cyto-
chrome-Casameasureof the ‘intrinsic’ signalingpathwayofapopto-
sis, wherein mitochondria release cytochrome-C from the
mitochondrial intermembrane space [16]. Indeed, MIN6 cells de-
pletedof50%endogenousPAK1releasedsubstantiallyelevatedlev-
els of cytochrome-C into the cytosolic fraction (Fig. 1B). These data
implicate PAK1 expression in a regulatory role to restrict expression
of apoptotic factors and the intrinsic apoptotic pathway in b-cells.
3.2. Hyperglycemia/glucotoxic stress increases Bad protein expression
in human and mouse pancreatic islets
Elevated fasting blood glucose is a hallmark characteristic of
individuals with frank T2D [3,17,18], wherein hyperglycemia is
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Bad protein has been implicated in glucolipotoxicity-induced b-cell
death [11,12]. To determine if hyperglycemia/glucotoxic stress was
sufﬁcient to alter Bad protein expression, human or mouse islets
were incubated in medium containing 5.8 or 25 mM glucose for
5 days, a model system used by others [12]. As shown in Fig. 2, glu-
cotoxicity was sufﬁcient to substantially elevate Bad protein levels
in both human and mouse islets.
3.3. PAK1 depletion results in enhanced Bad protein expression in islet
b-cells
Since PAK1 in known to phosphorylate Bad, which leads to Bad
degradation [13,14], we evaluated Bad and phosphorylated Bad
(pBad) levels in PAK1+/ (het) mouse islets. PAK1+/ heterozygous
mouse islets contained two-fold more Bad protein when com-
pared with PAK1+/+ wild-type (WT) islets (Fig. 3A). Bad expression
was also signiﬁcantly elevated in islets from PAK1/ KO mice
(2.1 ± 0.2 fold increase vs. WT, P < 0.05). Coincident with this, the
level of pBadSer112 was diminished in PAK1+/ islets, and when nor-
malized to total Bad levels, the relative amount of pBadSer112 in
these islets was reduced to 41 ± 8% (n = 3, P < 0.0002). In addition,
quantitative real-time PCR revealed an increase of Bad mRNA in
PAK1+/ Het islets (Fig. 3B), suggesting that in the islet, at least in
part, PAK1 regulates Bad protein expression via transcriptional
step.
Since islets contain a population of 20% of cells that are non-b
cells, we conﬁrmed that this Bad elevation was in the b-cells by
evaluating PAK1-depleted clonal MIN6 b-cells, which showed sig-
niﬁcantly increased Bad protein levels as well. Restoration of
PAK1 protein level by co-transfection with exogenous PAK1 corre-
spondingly normalized the aberrant increase in Bad protein in-
duced by PAK1-depletion (Fig. 3C). Overall these data suggest
that the abundance of PAK1 speciﬁcally in the b-cells of the islet
is important for maintaining a low level of Bad expression.
3.4. Hyperglycemia induced Bad up-regulation is exacerbated in
PAK1+/ heterozygous islets
We have shown that Bad expression in islets was increased by
chronic exposure to hyperglycemic conditions, or could be inducedHuman Islet A
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Fig. 2. Glucotoxic/hyperglycemic stress induced Bad protein levels in pancreatic b-
cells. (A) Human islets were incubated in CMRL in the presence of 5.8 or 25 mM
glucose for 5 days. Islets were then washed twice before harvesting and whole cell
lysates were subjected to immunoblotting with antibodies indicated. Data repre-
sent the average ± S.E. for three independent donor batches of human islets;
⁄P < 0.05, versus 5.8 mM glucose-treated islets. (B) Islets from wild type mice were
incubated in CMRL media in the presence of 5.8 or 25 mM glucose for 5 days. Islets
were then washed twice before harvesting. Whole cell detergent lysates were
subjected to immunoblotting with antibodies indicated. Data represent the
average ± S.E. for ﬁve sets of mouse islets; ⁄P < 0.05, versus 5.8 mM glucose.
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Fig. 3. Depletion of PAK1 increased Bad expression. (A) Bad expression increased in
PAK1+/ heterozygous (Het) islets. Islets were isolated from PAK1+/ Het and wild
type (WT) littermate mice and homogenized. Proteins were resolved by 12% SDS–
PAGE for immunoblotting with antibodies as indicated. Data represent the
average ± S.E. for ﬁve pairs of mice; ⁄P < 0.05, versus WT. (B) Bad mRNA expression
in PAK1+/ mice. Islets were isolated from PAK1+/ Het and littermate PAK1+/+ WT
mice for use in Q-PCR analysis (quantiﬁed relative to GAPDH from three batches of
islets, ⁄P < 0.05 versus WT). (C) MIN6 cells were transfected with PAK1 siRNA (+) or
control () oligonucleotides with pCMV6 vector or pCMV6-myc-PAK1 plasmid.
After 48 h incubation, cells were washed twice and incubated with glucose-free
MKRBB for 2 h before harvesting. Whole cell detergent lysates were prepared and
subjected to 12% SDS–PAGE for immunoblotting with antibodies indicated. Data
represent the average ± S.E. for three independent experiments; ⁄P < 0.05, versus
siCon.
Fig. 4. Hyperglycemia/glucotoxic stress induced Bad expression is exacerbated in
islets from PAK1+/ heterozygous (Het) mouse. Islets from WT or PAK1+/ Het mice
were incubated in the presence of 5.8 or 25 mM glucose for 5 days (Gluc, 5d). Islets
were then washed twice before harvesting. Detergent lysates were subjected to
immunoblotting with antibodies indicated. Data represent the average ± S.D. from
three independent batches of islets (⁄P < 0.05 versus WT islets in 5.8 mM glucose;
#P < 0.05 versus WT islets in 25 mM glucose).
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PAK1+/ Het islets subjected to hyperglycemia showed the largest
increase in Bad expression, suggesting that attenuated PAK1 abun-
dance could render islet b-cells more susceptible to apoptosis.
4. Discussion
Type 2 diabetes (T2D) occurs as a result of pancreatic b-cell fail-
ure in combination with insulin resistance in peripheral tissues. It
has been reported that at the onset of clinical diagnosis, there is a
50% reduction in b-cell mass in T2D, which has been attributed to
a 3- to 10-fold increase in b-cell apoptosis [2,3]. Implicated in the
progression to T2D is the upward rise in blood glucose levels
[3,17,18], and in the later stages of T2D, pro-inﬂammatory cyto-
kines on a base of chronically elevated blood glucose will ulti-
mately enhance b-cell death [19,20]. Thus, understanding the
details of how hyperglycemia, which begins prior to the onset of
frank T2D, leads to b-cell apoptosis will be essential for future
development of therapies that preserve b-cell mass and avoid the
otherwise inevitable progression towards b-cell failure and T2D
onset. Here we showed that hyperglycemic conditions or PAK1 loss
is sufﬁcient to trigger the up-regulation of Bad protein in islet b-
cells, while up-regulation of Bad protein level induced by glucotox-
ic stress was further exacerbated in PAK1+/mouse islets. This sug-
gests that PAK1 plays a role in restricting Bad protein abundance in
islet b-cells, and could confer protection against apoptosis under
stress.
We previously demonstrated that PAK1/ knockout mice show
normal b-cell mass and insulin content in islets [5], despite the
observations that Bad expression is elevated in islets from
PAK1/ knockout mice. One explanation for this discrepancymay be that the original b-cell mass determinations were made
in younger mice (10 weeks) wherein b-cell mass loss was not yet
or fully developed. Additionally or alternatively, it is also possible
that prolonged hyperglycemic stress is required to fully induce
Bad expression in vivo and hence drive b-cell apoptosis to yield
measureable loss of b-cell mass; PAK1/ mice at 10 weeks of
age did not show fasting hyperglycemia [5]. Considering this new
information showing the potential for PAK1 involvement in Bad
expression and apoptosis regulation, we plan to pursue longitudi-
nal studies of b-cell mass and apoptosis of the PAK1/ and PAK+/
mouse models, with inclusion of diet-induced stress to drive
hyperglycemia.
Our data suggest that PAK1 is required to control the level of
Bad in the b-cell, loss of PAK1 in islets from PAK+/ mouse leading
to a two-fold increase of protein expression. Q-PCR suggests that
PAK1 may regulate Bad protein expression at the transcriptional
level. However, our data suggest that PAK1 may also regulate
post-translationally, via phosphorylation of Bad, as supported by
our data showing reduced relative levels of pBad in PAK1+/ islets
as compared with WT. It has been shown that phosphorylation of
BadSer112 by several kinases control its stability [21,22]. PAK1 has
been shown to phosphorylate Bad in vitro and in vivo on Ser112
[13,14]. Thus, our data suggest that PAK1 may regulate Bad expres-
sion via phosphorylation-mediated degradation. Detailed mecha-
nisms of the regulation of Bad protein by PAK1 as well as the
potential regulation of additional members of the Bcl-2 family by
PAK1 are currently under investigation. In addition, it remains to
be tested whether PAK1 protein activation/signaling and/or scaf-
folding destabilize Bad protein.
In summary, these data implicate PAK1 as a new hub of suscep-
tibility for b-cell apoptosis, and we speculate that efforts to mini-
mize loss of PAK1 could assist to regain control over Bad levels.
Efforts to determine why PAK1 levels are attenuated in islets of
T2D patients are underway, to determine whether in response to
chronic hyperglycemia or otherwise, PAK1 protein is selectively re-
duced, ultimately rendering the islet more susceptible to apopto-
sis. Combined with the known positive role for PAK1 signaling in
glucose-stimulated insulin secretion and in peripheral insulin sig-
naling in skeletal muscle [5], PAK1 has potential as a therapeutic
target in diabetes.
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